In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.24% at $463.86. This change lagged the S&P 500's daily ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the meantime, other healthcare leaders could perform significantly better this year ...

If you are wondering whether Vertex Pharmaceuticals' current share price reflects its long term potential, a useful starting ...

Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...